London: Scientists have used pigs` brains to develop a `promising` new drug which they claim improves concentration, memory processing and mood in patients with a certain kind of dementia.
The new drug - called cerebrolysin - shows promise in treating patients with a certain kind of dementia known as vascular dementia, according to the results of a systematic review published in The Cochrane Library.
The drug is licensed in some countries for dementia, stroke and traumatic brain injury - although not yet in UK or US, the `Daily Mail` reported.
"Our review suggests that Cerebrolysin can help improve cognitive and global function in patients with mild to moderate severity vascular dementia," researcher Li He of the Department of Neurology at Sichuan University in Sichuan, China, said.
Cerebrolysin is a drug made from pig brain proteins that has produced some positive results from small vascular dementia trials. Larger trials are now underway.
The drug, however, is not easy to administer, with regular intravenous infusions necessary, said the review.
The review analysed the most up-to-date evidence from six trials involving 597 people.
All were given Cerebrolysin intravenously in different daily concentrations and for different treatment periods, from a few weeks to three years, depending on the trial.
Compared to standard care alone or placebos (dummy treatments), Cerebrolysin significantly improved brain function based on testing recall, arithmetic or other cognitive abilities.
It had a small positive effect on patients` overall clinical state and mood. Long-term treatment may have greater benefits, although most of the trials were short.
"The results are promising but due to low numbers of trials, inconsistencies between trials, risk of bias in the way some of the trials were conducted and lack of long-term follow-up, we cannot yet recommend Cerebrolysin as a routine treatment for vascular dementia," He said.
Since no serious side effects were reported due to taking the drug, He said that it indicated that Cerebrolysin is safe and well tolerated by patients with vascular dementia.
"But the fact that it has to be given in regular intravenous infusions means it could be impractical for use on a large scale," He added.
PTI
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Cookies Setting
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device and the processing of information obtained via those cookies (including about your preferences, device and online activity) by us and our commercial partners to enhance site navigation, personalise ads, analyze site usage, and assist in our marketing efforts. More information can be found in our Cookies and Privacy Policy. You can amend your cookie settings to reject non-essential cookies by clicking Cookie Settings below.
Manage Consent Preferences
Strictly Necessary Cookies
These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work or you may not be able to login.
Functional Cookies
These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly.
Targeting Cookies
These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They are also used to limit the number of times you see an advert as well as help measure the effectiveness of an advertising campaign. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.
Performance Cookies
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we may not know when you have visited our site, and may not be able to monitor its performance.